The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | The rationale for BTK degraders and their emerging role in resistant CLL
Kerry Rogers, MD, The Ohio State University, Columbus, OH, discusses the rationale behind BTK degraders and their potential role in resistant chronic lymphocytic leukemia (CLL). Dr Rogers explains how BTK degraders eliminate BTK, targeting its multiple functions and potentially overcoming resistance to both covalent and non-covalent BTK inhibitors. She highlights promising clinical activity in resistant CLL and the potential for future combination approaches. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
